Made in USA

Independently verifiedCertified

BPC-157 + TB-500 · 10mg + 10mg

Purity (HPLC)≥98%

LabVantage Analytical

Tested28 Jun 2026

Batch —·

Heavy metalsEndotoxinsMicrobialSolvents

View full COA

In stock

BPC-157 + TB-500

Name: BPC-157 + TB-500
Brand: AXOS
Availability: InStock

$119

Dual-peptide combination — angiogenesis and actin-mediated repair research

Buy 1, Get 1 Free · auto-applied

Add 2+ items to cart to activate the discount

VISAAMEXPayPal

Secure, encrypted checkout

Independently verifiedCertified

BPC-157 + TB-500 · 10mg + 10mg

Purity (HPLC)≥98%

LabVantage Analytical

Tested28 Jun 2026

Batch —·

Heavy metalsEndotoxinsMicrobialSolvents

View full COA

Frequently bought together

Researchers usually add these to complete the protocol.

BAC Water · 3ml

Essential · Extras

GHK-CU · 50mg

Recovery

$39

Melanotan 2 · 10mg

Tanning

$49

Add all (3)$97

Certificate of analysis

Every vial ships with its own report

We don't publish a brand-wide spec sheet and call it a “COA.” The certificate you receive references the actual lot number stamped on your vial — with the raw chromatograms attached.

Lot-specific HPLC purity + LC-MS identity
Raw chromatogram + mass confirmation attached
Signed off by the lab's Principal Chemist
Permanent archive — searchable by lot ID

View all lab reports

Reference reportView All Live Reports

Vantage Analytical

Independent analytical lab

Certificate of Analysis

RESULT · PASS

ProductBPC-157 + TB-500 · 10mg + 10mg

Lot / batch—

Reported28 Jun 2026

MethodHPLC-UV + LC-MS

AppearanceWhite lyophilized powder

ClientSolace Peptides

Analytical results

Identity (LC-MS)1419.5 DaPASS

Purity (HPLC-UV)≥98%PASS

Net content10.2 mgPASS

Endotoxin (LAL)< 0.05 EU/mgPASS

Heavy metals (ICP-MS)< 10 ppmPASS

Residual solventsBelow LOQPASS

HPLC Chromatogram

Purity ≥98%

Chemist verifiedDr. E. Hartley

Know your compound

What is BPC-157 + TB-500?

BPC-157 + TB-500 is a co-formulated vial containing two synthetic peptides — body protection compound-157 (BPC-157, pentadecapeptide) and thymosin beta-4 fragment (TB-500) — studied for their respective roles in vascular and cytoskeletal repair pathways. Each compound operates through a distinct molecular mechanism, making this pairing a common configuration in regenerative and orthopaedic research models.

BPC-157 upregulates VEGFR2 to drive angiogenesis and soft tissue repair, while TB-500 modulates actin polymerization to promote stem cell mobilization and attenuate fibrotic remodelling — two parallel, non-overlapping routes that preclinical investigators study together to interrogate complementary repair cascades. Animal models of tendon, muscle, and cardiac injury have been used to evaluate this combination in the context of both vascular support and cellular migration.

Accelerated tendon healing (50–72%) reported in animal models attributed to BPC-157 (Sikiric et al.)
TB-500 associated with stem cell mobilization and reduced fibrosis in cardiac injury models
Combination targets angiogenic and actin-regulatory pathways in parallel — studied as a dual-mechanism probe in musculoskeletal repair research

For research use only — not for human or veterinary use.

The research

What the research actually found

The published findings behind this compound — the headline numbers, in plain terms, each cited to source. Preclinical results are directional (animal / in-vitro) and shown for context, not as therapeutic claims.

Published research on the reference compound class. Provided for scientific context only — not a claim about the product supplied.

Tendon healingPreclinical

+50–72%

In animal models, BPC-157-treated subjects showed 50–72% faster tendon healing compared with untreated controls, according to research attributed to Sikiric et al. and reviewed in a 2026 orthopaedic sports medicine primer. Sample size and exact timeframe were not specified in the available source summary.

vs. untreated controls · animal models

Am J Sports Medicine 2026 · PMID 41476424

Untreated controlbaseline

BPC-157 treated+50–72% faster

Bar fill represents relative healing rate — animal models (Sikiric et al.); BPC-157 bar anchored at midpoint of reported 50–72% acceleration range.

Stem cell mobilizationPreclinical

TB-500 was associated with increased mobilization of stem cells to injury sites in preclinical cardiac models, suggesting a role in directing repair cells where they are needed. No specific magnitude or sample size was reported in the 2026 review source.

vs. untreated · cardiac injury model

Controllower

TB-500higher

Directional only — no precise magnitude reported in source. Bar heights reflect observed direction, not measured values. Cardiac injury animal model.

Sports Medicine (Auckland) 2026 · PMID 41966639

Evidence stagePreclinical

As of 2026, multiple independent review teams explicitly note that controlled human clinical trials are absent for both BPC-157 and TB-500. The entire evidence base remains preclinical — animal and cell models only.

Animal models

Tendon, muscle & cardiac injury studies

2026 Reviews

Mendias & Awan; Rahman et al. summarize preclinical body of work

Human trials

Controlled clinical data: absent as of 2026

Evidence stage as characterized by 2026 peer-reviewed reviews.

Sports Medicine (Auckland) 2026 · PMID 41966639

BPC-157 + TB-500 (10mg + 10mg) — molecular specimen

VEGFR2 Upregulationangiogenic signalling

Actin Modulationcytoskeletal regulation

Fibrosis Attenuationanti-fibrotic remodelling

Mechanism

How BPC-157 + TB-500 works

BPC-157 and TB-500 are studied to act through three distinct biological routes: receptor-mediated angiogenesis, actin-dependent cell migration, and attenuation of fibrotic remodelling.

VEGFR2 Upregulationangiogenic signalling

BPC-157 is studied to upregulate vascular endothelial growth factor receptor 2 (VEGFR2), a pathway researchers associate with promotion of new blood vessel formation and accelerated vascular support at sites of soft tissue injury in preclinical models.

Actin Modulationcytoskeletal regulation

TB-500 (thymosin beta-4 fragment) is investigated for its role in regulating G-actin sequestration, a mechanism linked to enhanced cell motility and the directional migration of progenitor and stem cells toward injury sites in animal studies.

Fibrosis Attenuationanti-fibrotic remodelling

TB-500 has been studied in cardiac and musculoskeletal injury models for its association with reduced scar tissue and myofibroblast activity, a distinct pathway from its migratory effects and one that researchers investigate separately as a determinant of tissue quality post-injury.

For research use only. Mechanisms described reflect published preclinical and clinical literature.

The process

How every batch is verified

01
Synthesized
Produced under controlled manufacturing with documented, repeatable processes.
02
HPLC purity
An independent lab reports the exact purity of every lot — a number, never a 'passes'.
03
Mass-spec identity
Molecular weight confirms the exact sequence is what the label says.
04
COA published
The certificate is posted to the open library, by lot, before the vial ships.

Verified researchers

Reviewed by people who test it themselves

Best sellers

Researchers reach for these

Best seller

5 Amino 1MQ

50mg

5.0

≥98% HPLC

$89

Best seller

BAC Water

10ml

5.0

$19

BPC-157

10mg

5.0

≥98% HPLC

$69

CJC / Ipamorelin

5mg + 5mg

5.0

>98% HPLC

$99

CJC-1295 with DAC

5mg

5.0

≥98% HPLC

$79

CJC-1295 without DAC

5mg

5.0

>98% HPLC

$69

FAQ

Frequently asked

Common questions about BPC-157 + TB-500

The COA guarantee

≥98% pure — or your money back.

Have any lot independently re-tested. If the results don't match the published certificate, we refund the order in full — no returns, no questions.

Order with cover

Third-party tested

An independent, accredited lab — no commercial interest in the result.

A COA on every lot

A lot-specific certificate ships with each vial, archived by batch.

Test it yourself → refund

Re-test any batch at any lab. A mismatch is a full refund.

Every vial ships with its own report

We don't publish a brand-wide spec sheet and call it a “COA.” The certificate you receive references the actual lot number stamped on your vial — with the raw chromatograms attached.

Lot-specific HPLC purity + LC-MS identity

Raw chromatogram + mass confirmation attached

Signed off by the lab's Principal Chemist

Permanent archive — searchable by lot ID

View all lab reports

What is BPC-157 + TB-500?

Accelerated tendon healing (50–72%) reported in animal models attributed to BPC-157 (Sikiric et al.)

TB-500 associated with stem cell mobilization and reduced fibrosis in cardiac injury models

Combination targets angiogenic and actin-regulatory pathways in parallel — studied as a dual-mechanism probe in musculoskeletal repair research

How BPC-157 + TB-500 works

BPC-157 and TB-500 are studied to act through three distinct biological routes: receptor-mediated angiogenesis, actin-dependent cell migration, and attenuation of fibrotic remodelling.

VEGFR2 Upregulationangiogenic signalling

Actin Modulationcytoskeletal regulation

Fibrosis Attenuationanti-fibrotic remodelling

For research use only. Mechanisms described reflect published preclinical and clinical literature.

Search

Search

Search

BPC-157 + TB-500

Every vial ships with its own report

What is BPC-157 + TB-500?

What the research actually found

How BPC-157 + TB-500 works

VEGFR2 Upregulationangiogenic signalling

Actin Modulationcytoskeletal regulation

Fibrosis Attenuationanti-fibrotic remodelling

How every batch is verified

Researchers reach for these

Frequently asked

What are BPC-157 and TB-500, and why are they studied together?

What does the preclinical research show for each component?

Is this combination FDA approved?

How is this combination used in research settings?

What is the molecular structure of each peptide in the vial?

How should this vial be stored?

≥98% pure — or your money back.

Search

Search

BPC-157 + TB-500

Every vial ships with its own report

What is BPC-157 + TB-500?

What the research actually found

How BPC-157 + TB-500 works

VEGFR2 Upregulationangiogenic signalling

Actin Modulationcytoskeletal regulation

Fibrosis Attenuationanti-fibrotic remodelling

How every batch is verified

Researchers reach for these

Frequently asked

What are BPC-157 and TB-500, and why are they studied together?

What does the preclinical research show for each component?

Is this combination FDA approved?

How is this combination used in research settings?

What is the molecular structure of each peptide in the vial?

How should this vial be stored?

≥98% pure — or your money back.